Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer

• Published in: Journal of clinical oncology Vol. 37; no. 15_suppl; p. 513
• Main Authors: Schneeweiss, Andreas, Loibl, Sibylle, Mamounas, Eleftherios P., Minckwitz, Gunter von, Mano, Max S., Untch, Michael, Huang, Chiun-Sheng, Rastogi, Priya, Conte, Pier Franco, D'hondt, Veronique, Redondo, Andres, Stamatovic, Ljiljana, Bonnefoi, Herve R., Castro Salguero, Hugo Raul, Fischer, Hans Holger, Wahl, Tanya A., Song, Chunyan, Blotner, Steven, Trask, Peter, Geyer, Charles E.
• Format: Journal Article
• Language: English
• Published: 20.05.2019

Abstract only 513 Background: The phase 3 KATHERINE (NCT01772472) study, met its primary endpoint by demonstrating significantly improved invasive disease-free survival with adjuvant T-DM1 compared to H in pts with residual invasive disease after neoadjuvant chemotherapy plus HER2-targeted therapy....